About this episode
Will tough times continue for psychedelic stocks? (1:50) Analyst Alex Carchidi shares his views on the sector and specific stocks like Compass Pathways (4:20), Atai and Cybin (19:50) and the inevitability of big pharma buying up assets (32:10).
Transcripts available on Seeking Alpha
Cybin: A Leading Early-Stage Psychedelics Play
American Medical Association approves CPT code for psychedelic therapies
FDA drafts new guidance on psychedelic research
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
Transcripts available on Seeking Alpha
Cybin: A Leading Early-Stage Psychedelics Play
American Medical Association approves CPT code for psychedelic therapies
FDA drafts new guidance on psychedelic research
Psychedelic Sunday: Scrutinizing Psychedelic Stocks
Get every episode summarized
Each time Investing Experts publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Investing Experts
Momentum, fear & the case for buying the dip
Investing Experts
Sep 3, 202628:56failed
Tax Loss Harvesting: Tax Alpha with Raul Shah
Investing Experts
Sep 2, 202624:02pending
Don't sleep on software
Investing Experts
Aug 25, 202643:04pending
Hedging exposure in this volatile market
Investing Experts
Aug 20, 202635:28pending